Amneal Pharmaceuticals (NASDAQ:AMRX) Raised to Strong-Buy at StockNews.com

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday.

Other equities analysts have also recently issued research reports about the stock. Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research report on Friday, September 6th. Truist Financial lifted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Finally, Barclays increased their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Trading Up 0.5 %

AMRX opened at $9.25 on Monday. The stock’s 50 day simple moving average is $8.54 and its 200-day simple moving average is $7.59. The stock has a market cap of $2.86 billion, a PE ratio of -13.53 and a beta of 1.17. Amneal Pharmaceuticals has a 1 year low of $4.15 and a 1 year high of $9.48.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Profund Advisors LLC boosted its stake in Amneal Pharmaceuticals by 8.1% in the second quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock worth $143,000 after purchasing an additional 1,680 shares in the last quarter. ProShare Advisors LLC increased its position in Amneal Pharmaceuticals by 8.6% in the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock valued at $133,000 after acquiring an additional 1,726 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Amneal Pharmaceuticals by 18.8% in the first quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock worth $122,000 after acquiring an additional 3,177 shares during the last quarter. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth about $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amneal Pharmaceuticals by 13.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after purchasing an additional 4,115 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.